Allergan (NYSE:AGN) has been assigned a $218.00 price objective by equities research analysts at Royal Bank of Canada in a report issued on Thursday. The brokerage presently has a “buy” rating on the stock. Royal Bank of Canada’s target price would indicate a potential upside of 26.53% from the stock’s current price.
A number of other analysts have also issued reports on AGN. ValuEngine lowered Allergan from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Mizuho reiterated a “buy” rating and issued a $267.00 price target on shares of Allergan in a report on Monday, September 25th. Barclays reiterated an “equal weight” rating on shares of Allergan in a report on Monday, October 2nd. Wells Fargo & Co reiterated an “outperform” rating and issued a $258.00 price target on shares of Allergan in a report on Wednesday, October 18th. Finally, UBS Group reiterated a “buy” rating and issued a $275.00 price target on shares of Allergan in a report on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $230.99.
Shares of Allergan (NYSE:AGN) traded up $0.71 during midday trading on Thursday, hitting $172.29. The company had a trading volume of 1,731,843 shares, compared to its average volume of 2,960,000. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $57,060.00, a price-to-earnings ratio of -7.63, a price-to-earnings-growth ratio of 1.18 and a beta of 1.11. Allergan has a 12-month low of $160.07 and a 12-month high of $256.80.
Allergan declared that its Board of Directors has approved a share repurchase program on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.
In related news, insider William Meury sold 11,807 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $173.89, for a total value of $2,053,119.23. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Brent L. Saunders acquired 4,600 shares of Allergan stock in a transaction that occurred on Wednesday, December 6th. The stock was acquired at an average cost of $164.74 per share, with a total value of $757,804.00. The disclosure for this purchase can be found here. Insiders purchased 17,630 shares of company stock valued at $2,890,057 in the last three months. 0.36% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of AGN. Abner Herrman & Brock LLC increased its position in shares of Allergan by 16.6% during the fourth quarter. Abner Herrman & Brock LLC now owns 4,275 shares of the company’s stock worth $699,000 after purchasing an additional 608 shares in the last quarter. Prudential Financial Inc. increased its position in shares of Allergan by 1.1% during the third quarter. Prudential Financial Inc. now owns 1,366,552 shares of the company’s stock worth $280,075,000 after purchasing an additional 14,440 shares in the last quarter. Atlantic Trust Group LLC increased its position in shares of Allergan by 8.2% during the third quarter. Atlantic Trust Group LLC now owns 702,369 shares of the company’s stock worth $143,950,000 after purchasing an additional 53,079 shares in the last quarter. AXA increased its position in shares of Allergan by 22.4% during the third quarter. AXA now owns 488,257 shares of the company’s stock worth $100,068,000 after purchasing an additional 89,257 shares in the last quarter. Finally, Shelton Capital Management increased its position in shares of Allergan by 35.4% during the third quarter. Shelton Capital Management now owns 4,117 shares of the company’s stock worth $844,000 after purchasing an additional 1,077 shares in the last quarter. 81.14% of the stock is owned by institutional investors.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
